[go: up one dir, main page]

ECSP11011150A - Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa - Google Patents

Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa

Info

Publication number
ECSP11011150A
ECSP11011150A EC2011011150A ECSP11011150A ECSP11011150A EC SP11011150 A ECSP11011150 A EC SP11011150A EC 2011011150 A EC2011011150 A EC 2011011150A EC SP11011150 A ECSP11011150 A EC SP11011150A EC SP11011150 A ECSP11011150 A EC SP11011150A
Authority
EC
Ecuador
Prior art keywords
glucoquinase
arilciclopropilacetamide
activators
derivatives
useful
Prior art date
Application number
EC2011011150A
Other languages
English (en)
Inventor
Melendo Ana Belen Bueno
Chicharro Francisco Javier Agejas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP11011150A publication Critical patent/ECSP11011150A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula:y composiciones farmacéuticas para el tratamiento de diabetes.
EC2011011150A 2008-12-19 2011-06-17 Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa ECSP11011150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19

Publications (1)

Publication Number Publication Date
ECSP11011150A true ECSP11011150A (es) 2011-07-29

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011150A ECSP11011150A (es) 2008-12-19 2011-06-17 Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa

Country Status (34)

Country Link
US (1) US8063079B2 (es)
EP (1) EP2379517B1 (es)
JP (1) JP5497064B2 (es)
KR (1) KR101290437B1 (es)
CN (1) CN102256952B (es)
AR (1) AR074470A1 (es)
AU (1) AU2009335931B2 (es)
BR (1) BRPI0923183B1 (es)
CA (1) CA2746746C (es)
CO (1) CO6382120A2 (es)
CR (1) CR20110342A (es)
DK (1) DK2379517T3 (es)
DO (1) DOP2011000197A (es)
EA (1) EA019055B1 (es)
EC (1) ECSP11011150A (es)
ES (1) ES2435242T3 (es)
HR (1) HRP20130983T1 (es)
IL (1) IL213210A (es)
JO (1) JO2979B1 (es)
MA (1) MA32902B1 (es)
MX (1) MX2011006434A (es)
MY (1) MY180567A (es)
NZ (1) NZ592930A (es)
PA (1) PA8851901A1 (es)
PE (1) PE20120339A1 (es)
PL (1) PL2379517T3 (es)
PT (1) PT2379517E (es)
SG (1) SG172256A1 (es)
SI (1) SI2379517T1 (es)
TN (1) TN2011000294A1 (es)
TW (1) TWI395748B (es)
UA (1) UA104742C2 (es)
WO (1) WO2010080333A1 (es)
ZA (1) ZA201103944B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123572A1 (en) 2010-03-31 2011-10-06 The Scripps Research Institute Reprogramming cells
WO2015075942A1 (ja) 2013-11-22 2015-05-28 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60108108T2 (de) 2000-05-03 2005-12-08 F. Hoffmann-La Roche Ag Heteroaromatische alkynylphenyl-verbindungen als glukokinase-aktivatoren
DE60106599T2 (de) 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
ES2307623T3 (es) 2000-05-08 2008-12-01 F. Hoffmann-La Roche Ag Activadores de fenilamida glucokinasa para-amina sustituida.
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
EP1585739B1 (en) 2003-01-06 2011-04-20 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
NZ541824A (en) * 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
CA2563192A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
CA2576407A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
AU2005311269B2 (en) * 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
WO2007005763A2 (en) * 2005-07-01 2007-01-11 Novartis Ag Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
JP2009504621A (ja) * 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
BRPI0618067A2 (pt) 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso e processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
AU2006310474A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
WO2008012227A2 (en) * 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
JP5207981B2 (ja) * 2007-01-10 2013-06-12 田辺三菱製薬株式会社 ヒドラゾン誘導体
ME02198B (me) 2008-04-28 2016-02-20 Kyorin Seiyaku Kk Derivati ciklopentilakrilamida

Also Published As

Publication number Publication date
CN102256952B (zh) 2013-12-11
EA019055B1 (ru) 2013-12-30
CA2746746A1 (en) 2010-07-15
MA32902B1 (fr) 2011-12-01
TN2011000294A1 (en) 2012-12-17
CN102256952A (zh) 2011-11-23
AR074470A1 (es) 2011-01-19
US8063079B2 (en) 2011-11-22
HRP20130983T1 (hr) 2013-11-22
UA104742C2 (uk) 2014-03-11
AU2009335931B2 (en) 2012-05-31
ZA201103944B (en) 2012-11-28
KR101290437B1 (ko) 2013-07-29
PE20120339A1 (es) 2012-04-16
BRPI0923183B1 (pt) 2019-03-19
MX2011006434A (es) 2011-07-19
EA201170845A1 (ru) 2011-12-30
PA8851901A1 (es) 2010-07-27
SI2379517T1 (sl) 2013-10-30
KR20110086751A (ko) 2011-07-29
IL213210A (en) 2015-03-31
EP2379517B1 (en) 2013-08-28
PL2379517T3 (pl) 2014-01-31
CR20110342A (es) 2011-09-14
JO2979B1 (en) 2016-03-15
WO2010080333A1 (en) 2010-07-15
IL213210A0 (en) 2011-07-31
DOP2011000197A (es) 2011-09-15
TW201029999A (en) 2010-08-16
BRPI0923183A8 (pt) 2017-09-12
DK2379517T3 (da) 2013-09-30
MY180567A (en) 2020-12-02
PT2379517E (pt) 2013-11-21
CA2746746C (en) 2013-09-24
US20100160395A1 (en) 2010-06-24
CO6382120A2 (es) 2012-02-15
SG172256A1 (en) 2011-07-28
EP2379517A1 (en) 2011-10-26
AU2009335931A1 (en) 2011-07-07
ES2435242T3 (es) 2013-12-17
JP5497064B2 (ja) 2014-05-21
TWI395748B (zh) 2013-05-11
NZ592930A (en) 2013-01-25
BRPI0923183A2 (pt) 2016-02-16
JP2012512874A (ja) 2012-06-07

Similar Documents

Publication Publication Date Title
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
MX2011005934A (es) Compuestos organicos.
DOP2012000006A (es) Agonista de gpr119
ECSP11011151A (es) Compuestos purina
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
ECSP11011184A (es) Compuestos orgánicos
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201270216A1 (ru) Фармацевтический состав
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
MX360330B (es) Regimen de administracion para nitrocatecoles.
GT200700074A (es) Fungicidas
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa